MLTX 48.71 MoonLake Immunotherapeutics
| Range: | 35.11-64.98 | Vol Avg: | 357856 | Last Div: | 0 | Changes: | 1.94 |
| Beta: | 1.26 | Cap: | 3.08B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue Oct 20 2020 | Empoloyees: | 50 | ||
| CUSIP: | 61559X104 | CIK: | 0001821586 | ISIN: | KY61559X1045 | Country: | CH |
| CEO: | Dr. Jorge Santos da Silva | Website: | https://www.moonlaketx.com | ||||
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Stock Details
Neutral 0.07
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 ZU...
globenewswire.com·Mon Sep 09 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow